Lupin Cements European Vision with €190M VISUfarma Eye Care Deal

MUMBAI, India – April 02, 2026 – Global pharmaceutical major Lupin Limited has finalized its acquisition of VISUfarma B.V., a prominent European ophthalmology firm, for an enterprise value of €190 million. The move, announced today, marks a significant strategic pivot for the Mumbai-based company, immediately establishing a formidable presence in Europe's lucrative specialty eye care market and fulfilling a long-stated goal of expanding its specialty franchise. The deal sees Lupin acquire VISUfarma from the London-based private equity firm GHO Capital Partners LLP, which had nurtured the company into a pan-European leader since 2016.

A Strategic Vision for European Expansion

For Lupin, the acquisition is far more than a simple purchase; it is the cornerstone of a meticulously planned expansion into the European specialty pharmaceutical landscape. The company has been vocal about its ambitions to build a robust specialty care portfolio beyond its established strongholds in India and the United States. The VISUfarma deal provides an immediate, turnkey solution to this strategic imperative.

VISUfarma brings with it a well-established commercial infrastructure across key European markets, including Italy, the UK, Spain, Germany, and France. This ready-made network, staffed by an experienced team with deep local market knowledge, saves Lupin years of groundwork and provides an instant platform for growth. Financially, the acquisition is expected to be immediately accretive, contributing positively to Lupin's sales growth and EBITDA margin from day one. VISUfarma reported revenues of approximately €53 million in 2025 with healthy EBITDA margins around 30 percent, making it a financially sound addition to Lupin's global operations.

"The VISUfarma acquisition marks a very exciting milestone for Lupin, adding a differentiated portfolio of more than 60 innovative eye health products supported by an established commercial infrastructure," said Vinita Gupta, CEO of Lupin, in the official announcement. "Beyond being immediately accretive, this strategic acquisition will also expand our presence across Europe and accelerate the build‑out of our specialty franchise."

Tapping into a Growing Market

The timing of the acquisition positions Lupin to capitalize on powerful demographic and public health trends sweeping across Europe. The continent's ophthalmology market, valued at an estimated USD 12.4 billion in 2024, is projected to surge to nearly USD 19 billion by 2030, growing at a robust annual rate of 7.3%. This expansion is not speculative; it is driven by undeniable forces.

A primary driver is Europe's aging population. As the continent's median age increases, so does the prevalence of age-related eye disorders such as cataracts, glaucoma, and age-related macular degeneration (AMD). Furthermore, the rising incidence of diabetes across Europe has created a parallel epidemic of diabetes-related eye complications. Diabetic retinopathy, a leading cause of blindness in working-age adults, affects an estimated 20% to 35% of people with diabetes in the region. This creates a significant and growing demand for advanced treatments and ongoing care.

VISUfarma's product portfolio is exceptionally well-aligned to meet these needs. With over 60 branded products, its offerings span critical areas including dry eye, glaucoma, retinal health, and eyelid hygiene. This allows the newly combined entity to address a wide spectrum of patient needs, from chronic conditions associated with aging and diabetes to issues like digital eye strain, a growing concern in modern society.

The Private Equity Playbook: GHO Capital's Successful Exit

The sale of VISUfarma also highlights the influential role of private equity in shaping the modern pharmaceutical industry. GHO Capital, a specialist healthcare investment firm, orchestrated the creation of VISUfarma in 2016. It did so by strategically combining the Italian founder-owned company Visufarma SpA with the European commercial operations of Nicox S.A.

Over the subsequent decade, GHO Capital executed a classic "buy-and-build" strategy. It invested heavily in infrastructure, professionalized the management team, and expanded the company's footprint from a domestic Italian player into a respected pan-European competitor. This journey culminated in the €190 million sale to Lupin, representing a successful and profitable exit for GHO and its investors. The transaction, valued at approximately 3.6 times VISUfarma's 2025 revenue, demonstrates the significant value that can be created by focusing and scaling specialty pharmaceutical assets. The exit further burnishes GHO's reputation as a savvy operator in the healthcare space, coming as the firm actively deploys capital from its recently closed €2.5 billion fourth fund.

Portfolio Power and Future Challenges

The integration of VISUfarma's portfolio dramatically enhances Lupin's capabilities in ophthalmology. The addition of specialty nutraceuticals and treatments for conditions like blepharitis complements Lupin's existing strengths and creates a comprehensive eye care division. This synergy was noted by Paolo Cioccetti, CEO Italy of VISUfarma, who expressed enthusiasm for the new chapter. "Their global expertise, vision, and commitment to ophthalmology make them the ideal partner to take VISUfarma to the next level," he stated.

However, the path forward is not without its challenges. Lupin will now face direct competition from entrenched global giants like Novartis, Roche, Alcon, and Santen, all of whom have significant market share in Europe. Successfully integrating VISUfarma's agile, European-centric operations with Lupin's large, global corporate structure will require careful management to preserve the very strengths that made VISUfarma an attractive target.

Furthermore, navigating Europe's complex and fragmented regulatory landscape will be a critical task. The stringent Medical Device Regulation (MDR), fully implemented in 2021, has raised the bar for market entry and requires robust post-market surveillance. Each country also has its own reimbursement and market access hurdles, demanding a sophisticated, localized strategy. Lupin's success will depend on its ability to harmonize these operations while continuing to innovate and meet the high standards of the European market. The acquisition is a bold first step, setting the stage for Lupin to become a significant force in European specialty healthcare.